A case of Bloom syndrome manifesting with therapy-related myelodysplastic syndromes harboring a novel BLM gene variant
International Journal of Hematology · 2024
DOI: 10.1007/s12185-024-03751-x ↗Kurz gefasst
Fallbericht in der Zeitschrift International Journal of Hematology, 2024. Verfasst von Takuma Ohashi und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan. Hauptthemen laut MEDLINE: Bloom Syndrome, RecQ Helicases, Myelodysplastic Syndromes. Die Arbeit nennt 15 Literaturangaben. Gefördert von: Japan Agency for Medical Research and Development, Japan Society for the Promotion of Science, Takeda Science Foundation.
Abstract (Originalsprache)
Bloom syndrome (BS) is an autosomal recessive genetic disorder caused by variants in the BLM gene. BS is characterized by distinct facial features, elongated limbs, and various dermatological complications including photosensitivity, poikiloderma, and telangiectatic erythema. The BLM gene encodes a RecQ helicase critical for genome maintenance, stability, and repair, and a deficiency in functional BLM protein leads to genomic instability and high predisposition to various types of cancers, particularly hematological and gastrointestinal malignancies. Here, we report a case of BS with a previously unreported variant in the BLM gene. The patient was a 34-year-old woman who presented with short stature, prominent facial features, and a history of malignancies, including lymphoma, breast cancer, and myelodysplastic syndromes (MDS). She was initially treated with azacitidine for MDS and showed transient improvement, but eventually died at age of 35 due to progression of MDS. Genetic screening revealed compound heterozygous variants in the BLM gene, with a recurrent variant previously reported in BS in one allele and a previously unreported variant in the other allele. Based on her characteristic clinical features and the presence of heterozygous variants in the BLM gene, she was diagnosed with BS harboring compound heterozygous BLM variants.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
- Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan. kunimoto@yokohama-cu.ac.jp.
- Department of Human Genetics, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
- Department of Rare Disease Genomics, Yokohama City University Hospital, Yokohama, Japan.
- Department of Clinical Genetics, Yokohama City University Hospital, Yokohama, Japan.
- Division of Medical Safety, Kanazawa University Hospital, Kanazawa, Japan.
Förderung
- Japan Agency for Medical Research and Development
- Japan Society for the Promotion of Science
- Takeda Science Foundation
Zitieren
APA
Ohashi, T., Kunimoto, H., Nukui, J., Teshigawara, H., Koyama, S., Miyazaki, T., Hagihara, M., Matsumoto, K., Koshimizu, E., Tsuchida, N., Hamanoue, H., Miyatake, S., Yachie, A., Matsumoto, N., & Nakajima, H. (2024). A case of Bloom syndrome manifesting with therapy-related myelodysplastic syndromes harboring a novel BLM gene variant. International Journal of Hematology. https://doi.org/10.1007/s12185-024-03751-x
Vancouver
Ohashi T, Kunimoto H, Nukui J, Teshigawara H, Koyama S, Miyazaki T, et al. A case of Bloom syndrome manifesting with therapy-related myelodysplastic syndromes harboring a novel BLM gene variant. International Journal of Hematology. 2024. doi:10.1007/s12185-024-03751-x
BibTeX
@article{Ohashi2024,
author = {Ohashi, Takuma and Kunimoto, Hiroyoshi and Nukui, Jun and Teshigawara, Haruka and Koyama, Satoshi and Miyazaki, Takuya and Hagihara, Maki and Matsumoto, Kenji and Koshimizu, Eriko and Tsuchida, Naomi and Hamanoue, Haruka and Miyatake, Satoko and Yachie, Akihiro and Matsumoto, Naomichi and Nakajima, Hideaki},
title = {A case of Bloom syndrome manifesting with therapy-related myelodysplastic syndromes harboring a novel BLM gene variant},
journal = {International Journal of Hematology},
year = {2024},
doi = {10.1007/s12185-024-03751-x}
}
EUVIMED